Multiple Myeloma News & Features
A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.
Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.
Genetically modifying immune cells might effectively treat multiple myeloma, according to a new study.
Blacks may be twice as likely as whites to develop multiple myeloma because they are more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance.
The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought.
Multiple Myeloma Clinical Trials
Sign Up for Free e-newsletters
- Risk prediction improved by new classification in chronic lymphocytic leukemia
- Treatment options for HER2-positive breast cancer
- Antimicrobial agent triclosan, used in soaps and detergents, may cause cancer
- The Society for Integrative Oncology (SIO) and co-researchers issue a report card on complementary therapies for breast cancer
- Disparities in non-small cell lung cancer (NSCLC) treatment based on race, treatment center
- A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia
- Early palliative care can cut hospital readmissions for cancer patients
- ONA Interview: Breaking the barriers to effective palliative care
- Fluorescent tattoos may improve self-esteem in patients receiving radiotherapy for breast cancer
- Cancer prehabilitation: One step toward improved outcomes
- Radiation exposure linked to aggressive thyroid cancers
- More patients opt for mastectomy despite limited, early-stage breast cancer
- Calcium channel blockers not found to increase risk of breast cancer
- Being overweight or obese may hide true nutritional status of patients with cancer
- Monitoring psychosocial function in radiotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|